Articles related to CLINICAL TRIALS

Semaglutide treatment led to more frequent improvement and less frequent deterioration in NYHA functional class compared to placebo in patients with obesity-related HFpEF over 52 weeks.

In a phase 3 trial, tisotumab vedotin showed a median overall survival of 11.5 months compared to 9.5 months with standard chemotherapy in patients with recurrent cervical cancer, representing a 30% reduction in the risk of death.

Dupilumab significantly induced histologic remission in 68% of children with eosinophilic esophagitis compared to 3% in the placebo group, according to a phase 3 trial.

This study reveals that individuals with autosomal dominant Alzheimer’s disease who are heterozygous for the APOE3 Christchurch variant experience a median delay in cognitive impairment onset of approximately five years compared to those without the variant.

In a Chinese study, tenecteplase administered 4.5 to 24 hours after stroke onset resulted in less disability at 90 days compared to standard treatment, though it carried a higher risk of symptomatic intracranial hemorrhage.

In a randomized trial of 1,412 patients with acute ischemic stroke, reteplase was more likely to result in excellent functional outcomes at 90 days compared to alteplase.